Peptides and BPC-157 for Pain: What's the deal?

Peptides in Pain Management: BPC-157, Risks, Reality, and the Business of Regenerative Medicine Episode Length: ~12–15 minutes Target Audience: Pain physicians, anesthesiologists, PM&R, sports medicine, and regenerative medicine clinicians Hosted by: Dr. David Rosenblum, MD Produced by: PainExam | NRAP Academy 🧠 Episode Overview Peptides like BPC-157 have exploded in popularity across regenerative medicine, sports medicine, and cash-based pain practices — but does the science support the hype? In this episode of PainExam, Dr. David Rosenblum takes a critical, evidence-based look at BPC-157 and other peptidesin pain management, examining: The biological rationale behind peptide therapy Preclinical and early human evidence for pain and tissue healing Regulatory status and safety concerns Ethical, legal, and marketing risks for physicians How peptides are currently being incorporated — and monetized — in pain practices This episode is designed to help clinicians separate science from marketing, and to approach peptide therapies with appropriate caution and professionalism. ⏱️ Episode Breakdown 🔹 00:00–01:30 — Introduction Why peptides are trending in pain and regenerative medicine What patients are asking — and what physicians need to know 🔹 01:30–04:30 — What Is BPC-157? Origins of Body Protection Compound-157 Mechanisms: angiogenesis, inflammation modulation, tissue repair Summary of preclinical data and animal pain models 🔹 04:30–07:00 — Evidence for Pain Relief & Healing Early inflammatory and non-inflammatory pain studies Intra-articular BPC-157 for knee pain: what the case series showed Why current human data are hypothesis-generating, not definitive 🔹 07:00–09:30 — Risks, Unknowns & Regulatory Issues FDA status and investigational use Quality, purity, and dosing variability Theoretical biologic risks and drug interactions 🔹 09:30–12:30 — The Business of Peptides in Pain Practice How peptides are marketed in regenerative clinics Cash-based models and patient demand Ethical marketing, informed consent, and medicolegal exposure 🔹 12:30–End — Clinical Takeaways Where peptides fit — and don't fit — in current pain practice Why evidence still matters in regenerative medicine ⚠️ Key Clinical Takeaways BPC-157 shows promising preclinical data, but human evidence remains limited Current studies lack randomization, controls, and long-term outcomes Peptides are not FDA-approved for pain or musculoskeletal indications Marketing peptides without transparency poses ethical and legal risk Physicians must clearly distinguish experimental therapies from standard of care 📚 Key References Discussed Józwiak et al. Multifunctionality and Possible Medical Application of BPC-157 — MDPI Pharmaceuticals (2025) McGuire et al. Regeneration or Risk? A Narrative Review of BPC-157 — Current Reviews in Musculoskeletal Medicine (2025) Sikirić et al. Effects of BPC-157 on Inflammatory and Non-Inflammatory Pain — Inflammopharmacology (1993) Lee & Padgett. Intra-Articular Injection of BPC-157 for Knee Pain — Alternative Therapies in Health and Medicine (2021) 📢 Sponsored Message / Advertisement 🔔 Ready to Master Evidence-Based Pain Medicine? If you're preparing for Pain Medicine boards or looking to strengthen your foundation in interventional and regenerative pain management, check out the educational resources at: 👉 https://www.nrappain.org 🎓 Offered through NRAP Academy: ✅ PainExam® Pain Management Board Review ✅ ABA, ABPM, FIPP, and ABIPP exam preparation ✅ Ultrasound-guided pain procedure training ✅ Regenerative pain medicine education — grounded in evidence, not hype ✅ Virtual Pain Fellowship curriculum All content is designed by practicing pain physicians, for practicing pain physicians. 🎯 Why Learn with NRAP Academy? Evidence-driv